Go here to see the original:

Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic...

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh